Sustainable low carbon cell-based platform for scale-up production of high-valued materials for personal care and biopharmaceuticals

基于可持续低碳细胞的平台，用于扩大个人护理和生物制药高价值材料的生产

• 批准号: 10059364
• 金额: $ 49.7万
• 依托单位: HEXISLAB LIMITED
• 依托单位国家: 英国
• 项目类别: Launchpad
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10059364
• 关键词: Sustainable; low; carbon; cell; based

Modern Cosmetics are full of ingredients from petroleum products and exotic plants. HLL is trying to change that by manufacturing these sustainably through engineering biology. This project funding will allow HLL to develop a scaled-up circular biomanufacturing process in the Tees Valley, contributing to the region's ambition of becoming the world's first Net Zero industrial cluster by 2040\. Funding will enable HLL to realise its goal as a manufacturer of high-value biochemicals using organic waste products coming from agricultural and marine waste as feedstock.The global beauty market is expected to grow from $483bn to $784bn by 2025, with nearly 70% of consumers demanding tailored and sustainable green products. The pharmaceutical lipid market is estimated to have a value of $100bn by 2028, growing at a rate of 7% annually, driven by the need for nanoparticles for vaccine and drug delivery.We aim to generate revenue from using our cellular platform and manufacturing process after securing significant investment to build a manufacturing facility in Teesside valley Industrial Zone, two years after the completion of this project. The project is pioneering and unlikely to be funded by private investors at this stage of development. Funding for this project will move the TRL from 5 to 7, making it attractive for private investment. With a fully developed platform, the project will deliver 24 new high-value ingredients for the cosmetic/pharmaceutical sector produced sustainably with estimated revenue of £100m in year 5, creating between 20 to 30 jobs in Tees valley and empowering a new global supply chain for the beauty, personal care, and pharmaceutical market right here in the UK.Deliverables from TU and HLL will be to demonstrate the scale-up of high-value ingredients such as cell signalling lipopeptides Matrikines, xanthones, biosurfactants (Fengecyin, Surfactin) and lipids which are not commercially obtainable through synthetic chemistry. It will assure potential customers and investors that we can manufacture at scale, de-risking the tech process and enabling us to engage with larger corporations. Provide pilot scale materials for customer testing, formulation, and evaluation. The process will enable the creation of process IP for designing, optimising, and producing novel materials for the global industry.

现代化妆品充满了石油产品和外来植物的成分。HLL正试图通过工程生物学可持续地制造这些来改变这一点。该项目资金将使HLL能够在Tees Valley开发规模扩大的循环生物制造工艺，为该地区到2040年成为世界上第一个净零工业集群的雄心做出贡献。HLL将利用来自农业和海洋废物的有机废物产品作为原料，实现其作为高价值生物化学品制造商的目标。全球美容市场预计将从4830亿美元增长到2025年的7840亿美元，近70%的消费者需要定制和可持续的绿色产品。预计到2028年，医药脂质市场的价值将达到1000亿美元，每年以7%的速度增长，这主要是由于疫苗和药物输送所需的纳米颗粒。我们的目标是在获得重大投资后，在Teesside valley工业区建立一个制造工厂，并在该项目完成两年后，通过使用我们的细胞平台和制造工艺来产生收入。该项目是开创性的，在目前的发展阶段不太可能得到私人投资者的资助。该项目的资金将使TRL从5增加到7，从而吸引私人投资。凭借一个全面开发的平台，该项目将为化妆品/制药行业提供24种新的高价值成分，可持续生产，预计第5年的收入为1亿英镑，在蒂斯谷创造20至30个就业机会，并为美容，个人护理，TU和HLL的产品将展示高价值成分的规模化，如细胞信号脂肽基质因子，氧杂蒽酮，生物表面活性剂（Fengecyin，Surfactin）和不能通过合成化学商购获得的脂质。它将向潜在客户和投资者保证，我们可以大规模生产，降低技术流程的风险，并使我们能够与更大的公司合作。为客户的测试、配方和评估提供中试规模的材料。该工艺将为全球工业设计、优化和生产新型材料创造工艺IP。